Original Research

Use of the melanoma vaccine in 38 dogs: The South African experience

Joanne L. McLean, Remo G. Lobetti
Journal of the South African Veterinary Association | Vol 86, No 1 | a1246 | DOI: https://doi.org/10.4102/jsava.v86i1.1246 | © 2015 Joanne L. McLean, Remo G. Lobetti | This work is licensed under CC Attribution 4.0
Submitted: 05 November 2014 | Published: 30 April 2015

About the author(s)

Joanne L. McLean, Bryanston Veterinary Hospital, Bryanston, South Africa
Remo G. Lobetti, Bryanston Veterinary Hospital, Bryanston, South Africa

Share this article

Bookmark and Share


The commercially available vaccine Oncept ® is indicated for the management of dogs with stage II or III oral melanoma after local control has been achieved. Survival times in dogs with both oral and digit melanoma have been shown to be significantly increased following vaccination. This retrospective study was designed to document the investigators’ experiences with Oncept ® vaccine when used as an adjunct therapy for treatment of stage II–IV oral, digit and malignant melanoma of other sites after local control had been achieved in dogs presented to a South African specialist referral veterinary practice. Thirty-eight dogs diagnosed with melanoma (25 oral, 6 digit and 7 infiltrative at various other sites) underwent a combination of surgical excision and Oncept ® vaccination. At the end of the study period there were 16 live and 22 dead dogs; median survival time of the live dogs was 29 months (range 2–46 months) versus 8 months (range 2–16 months) for those that died from progressive disease. This study showed that by using a combination of surgical excision and vaccination with Oncept ® survival times in dogs with malignant melanoma of the oral cavity, digit and other sites can be increased significantly.


Malignant melanoma, vaccine, dog


Total abstract views: 2576
Total article views: 4589


Crossref Citations

1. Recent clinical trials of cancer immunogene therapy in companion animals
Liliana ME Finocchiaro, Gerardo C Glikin
World Journal of Experimental Medicine  vol: 7  issue: 2  first page: 42  year: 2017  
doi: 10.5493/wjem.v7.i2.42